Stockreport

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity [Yahoo! Finance]

Scholar Rock Holding Corporation  (SRRK) 
Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report
PDF New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice; lean [Read more]